glp·helper
glphelper.com/semaglutide/alabama/auburn
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Auburn, AL

Verified Semaglutide providers in Auburn, AL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
25
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Alabama
25 of 25 shown

Find a Semaglutide provider in Alabama.

Every entry is checked against the NPI registry and the Alabama medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Alabama city · /semaglutide/alabama/{city}
§ 03Getting Semaglutide in Auburn
25 providers · Auburn, AL

How to get Semaglutide in Auburn.

25 GLP-1 prescribers and 6 local resource types are on record for Auburn, plus 3 nearby towns in the directory.

Prescribers in Auburn
25 prescribers
25 GLP-1 prescribers in Auburn, most listed as Family Medicine (12), Internal Medicine (9) and Family Medicine, Sports Medicine (3). Any Alabama-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Opelika (27 providers), Phenix City (19 providers) and Montgomery (38 providers).
Around the prescription in Auburn
6 listed nearby
6 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 4 places to move are on record near Auburn.
Medicaid (weight loss)
Diabetes only
As of April 2026, Alabama Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Alabama’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Auburn

Auburn, Alabama has a population of 76,143 people. The adult obesity rate in Auburn is an age-adjusted estimate of 38%, 0.9 percentage points below the Alabama state rate of 38.9%. Diagnosed diabetes reaches 11.8% of adults in Auburn. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 24.3% of adults in Auburn.

of Auburn adults have obesity
38%
diagnosed diabetes
11.8%
no regular physical activity
24.3%

Age-adjusted estimates for Auburn, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Semaglutide in Auburn
6 fitness clubs

The prescription is one part. Here is the rest, in Auburn.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Auburn, AL, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Opelika Sportsplex & Aquatics
FITNESS
4.6 on Google · 502 reviews
1001 SportsPlex Pkwy
Website
Frank Brown Recreation Center
REC CENTER
4.5 on Google · 215 reviews
235 Opelika Rd
Website
Infinity Wellness
FITNESS
5.0 on Google · 110 reviews
2459 E Glenn Ave
Website
Covington Recreation Center
REC CENTER
4.5 on Google · 86 reviews
213 Carver Ave
Website
Boggin' On The Plains
REC CENTER
4.8 on Google · 71 reviews
3935 US-29
Website
Auburn RV Field
REC CENTER
4.5 on Google · 47 reviews
Address not listed

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Kristty Bondurant, MS, RDN, LDN
RD
Registered dietitian
1158 Alan Ave Apt A
Call 334-740-5861NPI 1912889916
Sarah Brewer, MS, RD, LD
RD
Registered dietitian
2400 Hospital Rd
Call 334-524-5850NPI 1386218204
Sarah Bridges
RD
Registered dietitian
1220 Ferndale Dr
Call 334-728-5424NPI 1558254052
Rebecca Cannon, MS RDN
RD
Registered dietitian
1900 Samford Trace Ct Apt 1431
Call 256-655-7638NPI 1396638219
Jessica Deneke, RD, LD, CDE
RD
Registered dietitian
1829 Firestone Court
Call 334-590-5904NPI 1447554464
Jason Gilleland, RD
RD
Registered dietitian
258 Tallyho Dr
Call 404-271-9143NPI 1659846087
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Alabama

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Alabama

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]